Last Updated: November 16, 2026

Drug Sales Trends for LEVEMIR

« Back to Dashboard


Payment Methods and Pharmacy Types for LEVEMIR (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $270,835,193
INSIDE ANOTHER STORE $1,418,890,907
[disabled in preview] $1,474,424,775
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 644,227
INSIDE ANOTHER STORE 1,458,033
[disabled in preview] 2,731,018
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $322,440,037
MEDICARE $1,741,233,262
[disabled in preview] $1,100,477,575
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for LEVEMIR
Drug Units Sold Trends for LEVEMIR

Annual Sales Revenues and Units Sold for LEVEMIR

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
LEVEMIR ⤷  Start Trial ⤷  Start Trial 2022
LEVEMIR ⤷  Start Trial ⤷  Start Trial 2021
LEVEMIR ⤷  Start Trial ⤷  Start Trial 2020
LEVEMIR ⤷  Start Trial ⤷  Start Trial 2019
LEVEMIR ⤷  Start Trial ⤷  Start Trial 2018
>Drug Name >Revenues (USD) >Units >Year

Levemir Market Analysis, Sales Projections, Patent Position and Generic Entry Risk

Last updated: September 2, 2026

Levemir, Novo Nordisk's insulin detemir, is entering a managed phaseout rather than a conventional patent cliff. Novo Nordisk discontinued Levemir in the United States on December 31, 2024, after reducing supply during 2024. Global discontinuation plans are expected to remove most remaining sales by 2026, subject to country-specific supply and regulatory decisions.[1] The commercial impact is concentrated in diabetes basal-insulin markets, where patients and prescribers are shifting to Tresiba, Lantus, Toujeo, Basaglar, Semglee and other basal insulins.

Novo Nordisk's Levemir revenue has been declining for several years. A reasonable base case projects global sales falling from approximately DKK 8 billion to DKK 10 billion in 2023 to below DKK 2 billion by 2026, with residual sales largely eliminated by 2027. The largest commercial opportunity is product switching, not generic detemir entry.

What is Levemir and how is it used?

Levemir contains insulin detemir, a long-acting basal insulin administered by subcutaneous injection. It was developed by Novo Nordisk as a soluble, albumin-binding insulin analog with a prolonged duration of action.

Attribute Levemir
Active ingredient Insulin detemir
Originator Novo Nordisk
FDA application NDA 021536
U.S. approval June 2005
Therapeutic class Long-acting basal insulin
Primary indications Type 1 and type 2 diabetes
Dosage forms FlexTouch prefilled pen; vial presentations in selected markets
Main competitors Tresiba, Lantus, Toujeo, Basaglar, Semglee, Rezvoglar and biosimilar insulin glargine products
U.S. status Discontinued December 31, 2024
Regulatory category Insulin regulated as a biologic under the Public Health Service Act transition framework

The product is generally administered once or twice daily. Its clinical and commercial positioning has been weakened by the longer duration, lower dosing frequency, broader formulary access and stronger growth of newer basal insulins.

When did Levemir lose exclusivity?

Levemir's core composition-of-matter and insulin-analog patent protection expired years before its commercial discontinuation. The product therefore did not face a near-term loss of a single remaining U.S. patent that would have triggered the current decline.

The key commercial constraints are now supply rationalization and market substitution.

Milestone Date or period
Insulin detemir development and patent filings 1990s
U.S. approval of Levemir June 2005
Core U.S. patent protection Expired during the 2010s
Transition of insulin products to biologic regulation March 2020
Novo Nordisk announced U.S. discontinuation 2024
U.S. commercial discontinuation December 31, 2024
Expected broad global phaseout 2025-2026
Residual market after phaseout Primarily country-specific stock and access

The Orange Book historically listed Levemir-related patent information, but active U.S. patent protection is no longer the principal barrier to competition. Current market conditions are driven by manufacturing economics, regulatory requirements for follow-on insulin, physician switching and payer contracting.

What is the Orange Book status of Levemir?

Levemir was approved under NDA 021536 and its approved product information was listed in FDA drug databases. The Orange Book is less commercially determinative for Levemir than it is for a conventional small-molecule tablet because insulin is a biologic and follow-on products can proceed through the abbreviated 351(k) pathway.

The practical position is:

  • No meaningful remaining U.S. market exclusivity protects Levemir.
  • Core patent expiry does not automatically create an approved generic insulin detemir product.
  • Any competing insulin detemir would require substantial analytical, manufacturing and clinical-regulatory work.
  • The originator's discontinuation reduces the economic incentive to challenge patents or develop a new detemir product.
  • A Paragraph IV challenge is not the central entry mechanism for the current Levemir market.

How much revenue does Levemir generate?

Novo Nordisk reports product sales in Danish kroner. Levemir revenue has declined as patients moved to Tresiba and insulin glargine products and as insulin pricing pressure increased in the United States.

Public company reporting indicates the following approximate scale:

Period Estimated Levemir sales Approximate U.S. dollar equivalent* Direction
2021 DKK 11-12 billion $1.7-1.9 billion Declining
2022 DKK 10-11 billion $1.5-1.7 billion Declining
2023 DKK 8-10 billion $1.2-1.5 billion Accelerating decline
2024 DKK 5-7 billion $0.8-1.0 billion Sharp decline
2025E DKK 1-3 billion $0.15-0.45 billion Residual sales
2026E Below DKK 1 billion Below $0.15 billion Near phaseout
2027E onward Minimal Minimal Commercially immaterial

*Dollar conversions use approximate exchange rates and are intended for scale comparison, not reported-currency reconciliation.

Exact annual sales should be taken from Novo Nordisk's product-level annual reporting because exchange rates, geographic mix and reporting classifications affect dollar comparisons.[2]

What are the Levemir sales projections through 2028?

The base case assumes that Novo Nordisk completes most global discontinuation activity by 2026 and that remaining patients transition to alternative basal insulins.

Year Base-case global sales Base-case change Primary driver
2023A DKK 8-10 billion -10% to -20% Existing decline and switching
2024A DKK 5-7 billion -25% to -40% U.S. discontinuation and supply reduction
2025E DKK 1-3 billion -55% to -75% International phaseout
2026E Less than DKK 1 billion More than -60% Residual country sales
2027E Less than DKK 0.3 billion More than -60% Stock depletion and limited access
2028E De minimis — Commercial exit

Scenario analysis

Scenario 2025 sales 2026 sales 2028 sales Assumption
Accelerated exit DKK 0.5-1.5 billion Below DKK 0.3 billion Near zero Faster regulatory withdrawal and supply termination
Base case DKK 1-3 billion Below DKK 1 billion Near zero Broad phaseout completed by 2026
Delayed exit DKK 3-5 billion DKK 1-2 billion Below DKK 0.5 billion Continued sales in selected international markets

These are market-model projections, not Novo Nordisk guidance. The delayed-exit case would require continued commercial supply in countries where replacement access, reimbursement or regulatory transition takes longer.

Which companies are challenging Levemir commercially?

No company has established a major branded or biosimilar insulin detemir franchise comparable with insulin glargine competition. Levemir's commercial substitutes are primarily other basal insulins.

Competitor Company Molecule Competitive position
Tresiba Novo Nordisk Insulin degludec Primary internal replacement opportunity
Lantus Sanofi Insulin glargine Established reference basal insulin
Toujeo Sanofi Concentrated insulin glargine U-300 Longer-acting, concentrated formulation
Basaglar Eli Lilly and Boehringer Ingelheim Insulin glargine Follow-on insulin glargine
Semglee Viatris and Biocon Biologics Insulin glargine-yfgn Biosimilar/interchangeable insulin
Rezvoglar Eli Lilly Insulin glargine-aglr Follow-on insulin glargine
NPH insulin Multiple manufacturers Human insulin Lower-cost clinical alternative

The most important beneficiary is Tresiba because Novo Nordisk can retain patients within its basal-insulin portfolio. Sanofi and Lilly have stronger positions where payers prioritize lower net cost or where interchangeability supports pharmacy-level substitution.

What formulations are protected by Levemir patents?

Levemir's historical patent estate covered insulin detemir and related insulin derivatives, formulations and production concepts. The relevant protection generally addressed:

  • The insulin detemir molecular structure.
  • Acylated insulin derivatives with prolonged pharmacokinetics.
  • Pharmaceutical compositions containing insulin detemir.
  • Injectable formulations and excipient systems.
  • Production and purification methods.
  • Prefilled delivery-device presentations.

The strongest historical protection was the composition protection covering the insulin analog itself. Those patents have expired or no longer create a practical U.S. barrier. Formulation and device patents can have later expiry dates than the core molecule, but they do not preserve a commercially meaningful monopoly after the originator has withdrawn the product.

A representative early U.S. patent family associated with Novo Nordisk's insulin-derivative technology includes U.S. Patent No. 5,866,538. Its term expired in the 2010s under the applicable patent-term rules. Patent-family status differs by jurisdiction and continuation, so individual national records must be reviewed before litigation or licensing decisions.[3]

What patent litigation and Paragraph IV risks affect Levemir?

Levemir has no major current U.S. patent litigation profile comparable with high-revenue small-molecule products facing imminent generic entry.

Paragraph IV risk

Paragraph IV risk is low for three reasons:

  1. The core patents are expired or commercially weak.
  2. Levemir has been withdrawn from the largest regulated market.
  3. A developer would have limited return on investment from launching a new insulin detemir product while patients are already migrating to alternative basal insulins.

A future insulin detemir applicant could still encounter regulatory, manufacturing, device, labeling and interchangeability issues. Those issues are more important than patent invalidity or non-infringement litigation.

Settlement agreements

No major public patent settlement agreement has defined the Levemir market in the manner seen with several blockbuster oral drugs. The absence of a settlement-driven authorized generic launch is consistent with the product's long commercial decline and Novo Nordisk's decision to discontinue U.S. supply.

How strong is the Levemir patent estate?

The estate is historically important but commercially weak today.

Patent-estate factor Assessment
Core molecule protection Expired
Remaining U.S. exclusivity No meaningful commercial exclusivity
Formulation protection Limited practical value
Device protection Potentially relevant to specific presentations, not the molecule
Manufacturing know-how More important than patents
Biosimilar development barrier High
Litigation deterrence Low
Generic-entry economics Weak
Overall current strength Low for market exclusion; moderate for technical know-how

Novo Nordisk's manufacturing processes, analytical standards, cell-line or microbial production controls, device engineering and regulatory history may remain valuable even after patent expiry. Those assets can make direct replication expensive, but they do not prevent a technically capable competitor from pursuing a follow-on insulin.

What generic entry risks exist for Levemir?

The risk of a new generic or biosimilar Levemir is lower than the risk of substitution by existing basal-insulin products.

Regulatory barriers

Insulin is a complex biologic. A follow-on product must demonstrate high similarity through analytical characterization, manufacturing controls and appropriate clinical or pharmacodynamic evidence. A 351(k) applicant also faces interchangeability requirements if it seeks pharmacy-level substitution in the United States.[4]

Manufacturing barriers

Insulin detemir development requires:

  • Recombinant insulin manufacturing capacity.
  • Tight control of impurities and aggregation.
  • Validated potency and stability assays.
  • Consistent acylation and product characterization.
  • Pen or vial compatibility.
  • Cold-chain distribution.
  • Regulatory inspection readiness.

Commercial barriers

The market is unattractive for a new detemir entrant because:

  • The originator is leaving the market.
  • Patient volume is migrating to competing products.
  • Payers may favor established glargine products.
  • Tresiba has a direct internal switching advantage.
  • A new entrant would need to fund clinical, regulatory and manufacturing programs against a shrinking addressable market.

The probability of significant new Levemir-specific competition is therefore low. Generic and biosimilar competition is more likely to target insulin glargine, insulin lispro, insulin aspart or other products with larger continuing markets.

How does Levemir compare with Tresiba, Lantus and biosimilar glargine?

Metric Levemir Tresiba Lantus/Toujeo Biosimilar glargine
Molecule Detemir Degludec Glargine Glargine
Originator Novo Nordisk Novo Nordisk Sanofi Multiple
Current market direction Exit Growth and switching beneficiary Mature, large base Expanding price pressure
Dosing profile Long-acting, often once or twice daily Ultra-long acting Long-acting Comparable to glargine reference
Patent relevance Largely exhausted More relevant historical and formulation estate Core protection expired; device/formulation issues remain Competes through follow-on pathway
Main commercial advantage Established patient familiarity Internal Novo replacement Scale and payer presence Lower net price and interchangeability
Levemir displacement risk — High High Moderate to high

Tresiba is the most direct replacement for patients who want a Novo Nordisk basal insulin. Lantus and Toujeo remain important in formularies with established Sanofi contracting. Biosimilar glargine products can capture price-sensitive patients and payer volume.

What is the FDA regulatory status of Levemir?

Levemir was approved by the FDA under NDA 021536. Novo Nordisk's U.S. discontinuation means the product is no longer a continuing commercial option for new prescribing in the United States after the announced withdrawal date. FDA discontinuation records distinguish commercial discontinuation from safety withdrawal; Levemir's phaseout was a business and supply decision rather than a safety recall.[1,5]

The regulatory consequences include:

  • Reduced U.S. availability of Levemir pens and vials.
  • Increased conversion activity to alternative basal insulins.
  • Need for patient-specific dose titration during switching.
  • Continued country-by-country regulatory treatment outside the United States.
  • Lower value of U.S. Levemir-specific regulatory infrastructure.

What licensing deals affect Levemir?

No major recent licensing deal has materially changed the Levemir market outlook. Novo Nordisk retains the relevant originator know-how and commercial rights, while insulin glargine competitors have built separate portfolios through originator development, biosimilar partnerships and follow-on manufacturing arrangements.

The principal commercial transaction opportunity is not Levemir licensing. It is the acquisition or transfer of manufacturing, supply or patient-transition assets tied to Novo Nordisk's broader insulin portfolio. Levemir-specific licensing would have limited strategic value unless linked to an established low-cost insulin manufacturing platform and an existing reimbursement channel.

What is the geographic coverage and market opportunity?

Levemir's remaining opportunity is concentrated outside the United States, but the geographic market is shrinking.

Region Outlook
United States Commercially discontinued
Europe Declining, with replacement by degludec and glargine products
Japan Mature market with substitution risk
China Price pressure and local insulin competition
Latin America Possible residual demand, subject to supply and reimbursement
Middle East and Africa Access may persist longer in selected markets
Other emerging markets Potential residual sales, but low margin and high supply sensitivity

The geographic phaseout will likely be uneven. Countries with constrained access to Tresiba or newer glargine products may maintain Levemir use longer. That does not create a durable growth market because each additional year of supply requires Novo Nordisk to maintain manufacturing, quality and distribution infrastructure for a declining product.

What is the revenue exposure for Novo Nordisk and competitors?

Levemir's direct revenue exposure is modest relative to Novo Nordisk's total sales but meaningful within its legacy insulin portfolio. The larger financial issue is where displaced patients go.

Novo Nordisk

Novo Nordisk can convert a portion of Levemir patients to Tresiba. This may preserve revenue but will not fully offset Levemir sales because:

  • Tresiba has different pricing and reimbursement terms.
  • Some patients will move to glargine products.
  • Some will move to human insulin because of affordability.
  • U.S. payer contracts may favor competitors.
  • Product discontinuation creates temporary transition costs.

Sanofi

Sanofi is positioned to capture patients through Lantus and Toujeo, especially in plans with established Sanofi insulin contracting. Toujeo can appeal to patients needing concentrated basal insulin.

Eli Lilly and Viatris/Biocon

Lilly's Basaglar and Rezvoglar and Viatris/Biocon's Semglee can benefit from payer-led substitution. Their opportunity is strongest where reimbursement favors lower-cost follow-on insulin glargine.

Key Takeaways

  • Levemir is in commercial phaseout, not at the start of a conventional generic cliff.
  • U.S. discontinuation occurred on December 31, 2024.
  • Global sales are likely to fall below DKK 1 billion by 2026 and become immaterial by 2027-2028.
  • Core insulin detemir patent protection has expired; patents are not the main current market barrier.
  • New generic or biosimilar detemir entry is commercially unlikely because the addressable market is shrinking.
  • Tresiba is Novo Nordisk's leading internal replacement product.
  • Lantus, Toujeo, Basaglar, Semglee and Rezvoglar are the principal external beneficiaries.
  • The main value lies in patient conversion, payer contracting and manufacturing know-how rather than Levemir-specific licensing.
  • The largest risks are supply disruption, patient switching, reimbursement friction and loss of physician familiarity.

FAQs

Is Levemir still available in the United States?

No. Novo Nordisk discontinued U.S. Levemir supply on December 31, 2024. Patients generally require conversion to another basal insulin under prescriber supervision.

Is there a generic version of Levemir?

There is no widely commercialized generic or biosimilar insulin detemir product that has replaced Levemir at scale. The market is shifting toward insulin glargine and insulin degludec rather than a new detemir entrant.

What drug is most similar to Levemir?

Tresiba is the closest Novo Nordisk replacement because it is also a long-acting basal insulin. Lantus, Toujeo and follow-on insulin glargine products are the main competitive alternatives.

Will Levemir sales reach zero?

Global sales may persist temporarily in countries with remaining inventory, regulatory transition periods or limited access to replacement products. Commercially meaningful revenue is unlikely after 2026.

Can a company still develop insulin detemir?

A company could pursue a follow-on insulin detemir through applicable biologic pathways, but the shrinking market, manufacturing complexity and established alternatives make the investment case weak.

References

  1. Novo Nordisk A/S. (2024). Annual report 2024 and Levemir discontinuation communications. Novo Nordisk.
  2. Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.
  3. United States Patent and Trademark Office. (1999). U.S. Patent No. 5,866,538, Insulin derivatives. U.S. Department of Commerce.
  4. U.S. Food and Drug Administration. (2024). Questions and answers on biosimilar and interchangeable insulin products. U.S. Department of Health and Human Services.
  5. U.S. Food and Drug Administration. (2024). Drugs@FDA: Levemir, NDA 021536. U.S. Department of Health and Human Services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.